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The Lessons of COURAGE
for the Management of
Stable Coronary Artery Disease*
Thomas E. Kottke, MD, MSPH
Minneapolis, Minnesota
As accountable care organizations are implemented, the
basis of compensation for cardiologists can be expected to
migrate from fee-for-service to effective and efficient man-
agement of episodes of care. The most successful groups of
cardiologists will learn to use diagnostic and therapeutic
procedures judiciously. The COURAGE (Clinical Out-
comes Utilizing Revascularization and Aggressive Drug
Evaluation) trial report (1) in this issue of the Journal
answers 2 important questions about how to achieve this
goal: 1) “Is it important to make the diagnosis of metabolic
syndrome (MetS) when managing patients with stable
coronary artery disease (CAD)?” 2) “Is the presence of MetS
an indication for percutaneous coronary intervention (PCI)
in stable patients with CAD?” The answer to each question
is “No.” Although patients with MetS fare worse than
patients without this condition, all of the risk information is
explained by the risk factors that can be treated directly; in
addition, whether or not they have MetS or diabetes, stable
CAD patients who receive the indicated evidence-based
medical therapies do not have a mortality or morbidity
benefit from PCI.
See page 131
Because these conclusions may challenge the thinking
and practice of many cardiologists, the design of the
COURAGE trial deserves to be reviewed in detail. COUR-
AGE was organized to test the hypothesis that clinical
outcomes (i.e., death, nonfatal myocardial infarction [MI],
and quality of life) would be superior for patients randomly
assigned to PCI and intensive medical therapy than for
those randomly assigned to intensive medical therapy alone
(2). All subjects were followed for at least 2.5 years. Study
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(AHA)/American College of Cardiology (ACC) Joint Task
Force Class I (definite) or II (probable) indications for PCI
(3). The only exclusion criteria were: unstable angina; rest
angina, shock, or persistent heart failure after MI; left main
disease; a depressed ejection fraction; cardiogenic shock;
pulmonary edema unresponsive to medical therapy; recent
revascularization, significant valvular disease; primary car-
diac muscle disease; resuscitation from out-of-hospital car-
diac arrest or symptomatic ventricular tachycardia; or un-
controllable hypertension.
All subjects were given goals for smoking (no smoking);
diet (low in saturated fat); physical activity (30 to 45 min of
moderate-intensity activity 5 times per week supplemented
by an increase in daily lifestyle activities; and weight (body
mass index [BMI] 25 kg/m2 or a 10% relative weight loss
if the initial BMI was 27.5 kg/m2). All subjects were
rescribed 81 to 325 mg/day of aspirin or, if allergic to
spirin, clopidogrel at 75 mg/day. Beta-blockers and
ngiotensin-converting enzyme (ACE) inhibitors were also
onsidered standard therapy. The blood pressure goal was
130/85 mm Hg, and an ACE inhibitor was first-line
herapy. The low-density lipoprotein (LDL) cholesterol
oal was 60 to 85 mg/dl. Up to 80 mg of simvastatin daily
as prescribed alone or in combination with ezetimibe to
chieve this goal. A fasting blood glucose level of 80 to 125
g/dl and a hemoglobin A1c level 7.0% was the goal for
iabetes control (2).
During a follow-up period of 2.5 to 7.0 years (median: 4.6
ears), the PCI group had 211 primary events, and the
edical-therapy group had 202 events. There were no
ignificant differences between the PCI group and the
edical-therapy group in the composite endpoint of death,
I, and stroke; hospitalization for acute coronary syn-
rome; or MI.
Although clinical trials provide prima facie evidence that
spirin, beta blockers, statins, and ACE inhibitors reduce
ubsequent event rates and improve survival in certain
atients with CAD, observations from medical practice
how that the difference in survival between patients who
dhere to none of the evidence-based interventions and
hose who adhere to all of them is as high as 80% to 90%
4–8). On the other hand, observations from clinical
ractice also reaffirm doubts about the utility of PCI to
educe MI, death, and other hard endpoints in patients who
o not have elevated biomarkers (9). If PCI has no utility in
table CAD patients, neither does routine testing for
schemia. The heart of effective ambulatory cardiology
ractice is helping patients adhere to tobacco, nutrition, and
hysical activity lifestyle goals; helping them adhere to
fficacious medications; and controlling their hypertension
nd dyslipidemia.
Optimizing the care of ambulatory patients with CAD
ould have a significant impact on premature deaths. About
% of Americans in the 30- to 84-year-old age bracket meet
139JACC Vol. 58, No. 2, 2011 Kottke
July 5, 2011:138–9 The Lessons of COURAGEthe COURAGE inclusion criteria, and another 1% to 2%
have CAD with a significantly decreased ejection fraction
(10). On the basis of statistics reported by the AHA and the
results of clinical trials, we have calculated that fully imple-
menting a program like COURAGE for all ambulatory
patients with CAD would prevent or postpone about a
quarter of all deaths in persons ages 30 to 84 years (10). This
would be about 3 times the impact of optimizing care for
patients hospitalized for acute heart disease events.
Failure to adhere to goal lifestyle and medication regi-
mens in the long term is a significant problem for patients
with CAD (11). However, the use of disease-management
tools increases adherence (12), and 2 tools have been
designed specifically for use by cardiologists: the AHA
program Get With the Guidelines–Outpatient (13) and the
ACC’s Practice Innovation and Clinical Excellence (PIN-
NACLE) registry (14). These management tools can help
cardiologists increase the value of their services by improv-
ing outcomes and increasing the effectiveness and efficiency
of care. Cardiologists who take the findings of COURAGE
to heart and implement management programs for their
ambulatory patients with CAD will be both fulfilling a
contract with their patients to deliver the best possible care
and increasing the viability of their own practices.
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